Coagulation and thrombin generation assay parameters
| Group . | Sample . | aPTT (sec) . | aPTT + FVa (sec) . | ETP (nM·min) . | Peak height (nM) . | Time to peak (min) . | ETP + FVa (nM·min) . | Peak height + FVa (nM) . | Time to peak + FVa (min) . | t1/2 (min) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Control | NHP | 38 ± 0.4 | ND | 5700 | 370 | 29 | — | — | — | — |
| Control | HB | 110 ± 4 | ND | NA | NA | NA | NA | NA | NA | — |
| Control | HB + FIX | 40 ± 0.4 | ND | 4800 | 370 | 14 | — | — | — | — |
| Wild-type | HB + wt-FXa | 32 ± 1 | 25 ± 0.3 | 2700 | 120 | 17 | 3600 | 170 | 17 | 1.15 ± 0.05 |
| Group 1 | HB +FXa-V17M | 41 ± 0.4 | 31 ± 0.9 | 4500 | 270 | 14 | 4500 | 230 | 17 | 11 ± 0.4 |
| Group 2 | HB + FXa-I16L | 54 ± 2 | 33 ± 2 | 3900 | 200 | 17 | 4300 | 200 | 18 | 41 ± 3.5 |
| HB + FXa-V17T | 47 ± 2 | 29 ± 1 | 4000 | 200 | 15 | — | — | — | 79 ± 5.5 | |
| HB + FXa-I16M | 60 ± 4 | 39 ± 2 | 3000 | 160 | 18 | 3900 | 190 | 18 | 115 ± 10 | |
| Group 3 | HB + FXa-V17S | 76 ± 4 | 45 ± 2 | 3800 | 170 | 20 | 3600 | 170 | 17 | 307 ± 12.5 |
| HB + FXa-I16T | 94 ± 1 | 73 ± 2 | 300 | 25 | 24 | 2000 | 100 | 16 | 447 ± 29 |
| Group . | Sample . | aPTT (sec) . | aPTT + FVa (sec) . | ETP (nM·min) . | Peak height (nM) . | Time to peak (min) . | ETP + FVa (nM·min) . | Peak height + FVa (nM) . | Time to peak + FVa (min) . | t1/2 (min) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Control | NHP | 38 ± 0.4 | ND | 5700 | 370 | 29 | — | — | — | — |
| Control | HB | 110 ± 4 | ND | NA | NA | NA | NA | NA | NA | — |
| Control | HB + FIX | 40 ± 0.4 | ND | 4800 | 370 | 14 | — | — | — | — |
| Wild-type | HB + wt-FXa | 32 ± 1 | 25 ± 0.3 | 2700 | 120 | 17 | 3600 | 170 | 17 | 1.15 ± 0.05 |
| Group 1 | HB +FXa-V17M | 41 ± 0.4 | 31 ± 0.9 | 4500 | 270 | 14 | 4500 | 230 | 17 | 11 ± 0.4 |
| Group 2 | HB + FXa-I16L | 54 ± 2 | 33 ± 2 | 3900 | 200 | 17 | 4300 | 200 | 18 | 41 ± 3.5 |
| HB + FXa-V17T | 47 ± 2 | 29 ± 1 | 4000 | 200 | 15 | — | — | — | 79 ± 5.5 | |
| HB + FXa-I16M | 60 ± 4 | 39 ± 2 | 3000 | 160 | 18 | 3900 | 190 | 18 | 115 ± 10 | |
| Group 3 | HB + FXa-V17S | 76 ± 4 | 45 ± 2 | 3800 | 170 | 20 | 3600 | 170 | 17 | 307 ± 12.5 |
| HB + FXa-I16T | 94 ± 1 | 73 ± 2 | 300 | 25 | 24 | 2000 | 100 | 16 | 447 ± 29 |
Concentrations: FXa, 0.1 nM; FVa, 10-20 nM when added; FIX, 5 µg/mL.
HB, hemophilia B; NA, not applicable; ND, not determined; NHP, normal human plasma.